NCT02860507.

Trial name or title	Study to determine if administration of sugammadex impacts hospital efficiency
Methods	Allocation: randomized Endpoint classification: efficacy study Intervention model: parallel assignment Masking: double‐blind (participant, caregiver, investigator, outcomes assessor) Primary purpose: treatment
Participants	Estimated enrolment: 50 Inclusion criteria: Scheduled for open ventral hernia repair or open colectomy ASA class I to III ≥ 18 years of age Body mass index (BMI) < 45 kg/m2 and weight < 150 kg Written informed consent Exclusion criteria: Medical conditions and/or surgical procedures that are not compatible with use of the TOF‐Watch SX (e.g. injuries to the thumbs/distal forearms, bilateral ulnar nerve damage, cardiac pacemaker) Known or suspected neuromuscular disorders impairing neuromuscular blockade (e.g. myasthenia gravis) Known or suspected significant renal dysfunction (e.g. creatinine clearance < 30 mL.min‐1) Known or suspected family history of malignant hyperthermia; significant hepatic dysfunction Known or suspected allergy to opiates/opioids, muscle relaxants, or other medications used during general anaesthesia Known or suspected hypersensitivity to sugammadex or other cyclodextrins or rocuronium or any of its excipients Contraindication to rocuronium or sugammadex Pregnancy Morbid obesity with BMI > 45 kg/m2 or weight > 150 kg
Interventions	Neostigmine 0.06 mg/kg and glycopyrrolate 0.04 mg/kg IV Sugammadex 4 mg/kg
Outcomes	Primary outcome measures: Operating room (OR) turnover time when sugammadex is used instead of combination of neostigmine and glycopyrrolate [Time Frame: through start of next surgery, average of 2 hours] [Designated as safety issue: no] Secondary outcome measures: Number of participants who experience postoperative nausea and vomiting, postoperative pain, and postoperative complications [Time Frame: through discharge from hospital, average of 72 hours] [Designated as safety issue: no]
Starting date	August 2016
Contact information	Enrico Camporesi, Attending Anesthesiologist & Director of Research, SE, University of South Florida
Notes	This study is enrolling participants by invitation only. Estimated Primary Completion Date: May 2017